Clinical use of the co-formulation of insulin degludec and insulin aspart.
Identifieur interne : 001A13 ( PubMed/Curation ); précédent : 001A12; suivant : 001A14Clinical use of the co-formulation of insulin degludec and insulin aspart.
Auteurs : A. Kumar [Inde] ; T. Awata [Japon] ; S C Bain [Royaume-Uni] ; A. Ceriello [Espagne] ; G R Fulcher [Australie] ; A G Unnikrishnan ; R. Arechavaleta [Mexique] ; G. Gonzalez-Gálvez [Mexique] ; T. Hirose [Japon] ; P D Home [Royaume-Uni] ; K. Kaku [Japon] ; L. Litwak [Argentine] ; S. Madsbad [Danemark] ; M. Pinget [France] ; R. Mehta [Mexique] ; A. Mithal [Inde] ; M. Tambascia [Brésil] ; J. Tibaldi [États-Unis] ; J S Christiansen [Danemark]Source :
- International journal of clinical practice [ 1742-1241 ] ; 2016.
Descripteurs français
- KwdFr :
- Calendrier d'administration des médicaments, Diabète de type 1 (traitement médicamenteux), Diabète de type 2 (traitement médicamenteux), Essais cliniques de phase II comme sujet, Essais cliniques de phase III comme sujet, Glycémie, Humains, Hypoglycémiants (effets indésirables), Hypoglycémiants (pharmacologie), Hypoglycémiants (usage thérapeutique), Insuline Asparte (administration et posologie), Insuline Asparte (effets indésirables), Insuline Asparte (pharmacologie), Insuline à longue durée d'action (administration et posologie), Insuline à longue durée d'action (effets indésirables), Insuline à longue durée d'action (pharmacologie), Résultat thérapeutique, Substitution de médicament.
- MESH :
- administration et posologie : Insuline Asparte, Insuline à longue durée d'action.
- effets indésirables : Hypoglycémiants, Insuline Asparte, Insuline à longue durée d'action.
- pharmacologie : Hypoglycémiants, Insuline Asparte, Insuline à longue durée d'action.
- traitement médicamenteux : Diabète de type 1, Diabète de type 2.
- usage thérapeutique : Hypoglycémiants.
- Calendrier d'administration des médicaments, Essais cliniques de phase II comme sujet, Essais cliniques de phase III comme sujet, Glycémie, Humains, Résultat thérapeutique, Substitution de médicament.
English descriptors
- KwdEn :
- Blood Glucose, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Diabetes Mellitus, Type 1 (drug therapy), Diabetes Mellitus, Type 2 (drug therapy), Drug Administration Schedule, Drug Substitution, Humans, Hypoglycemic Agents (adverse effects), Hypoglycemic Agents (pharmacology), Hypoglycemic Agents (therapeutic use), Insulin Aspart (administration & dosage), Insulin Aspart (adverse effects), Insulin Aspart (pharmacology), Insulin, Long-Acting (administration & dosage), Insulin, Long-Acting (adverse effects), Insulin, Long-Acting (pharmacology), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Insulin Aspart, Insulin, Long-Acting.
- chemical , adverse effects : Hypoglycemic Agents, Insulin Aspart, Insulin, Long-Acting.
- chemical , pharmacology : Hypoglycemic Agents, Insulin Aspart, Insulin, Long-Acting.
- chemical , therapeutic use : Hypoglycemic Agents.
- chemical : Blood Glucose.
- drug therapy : Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2.
- Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Drug Administration Schedule, Drug Substitution, Humans, Treatment Outcome.
Abstract
To provide a review of the available data and practical use of insulin degludec with insulin aspart (IDegAsp). Premixed insulins provide basal and prandial glucose control; however, they have an intermediate-acting prandial insulin component and do not provide as effective basal coverage as true long-acting insulins, owing to the physicochemical incompatibility of their individual components, coupled with the inflexibility of adjustment. The molecular structure of the co-formulation of IDegAsp, a novel insulin preparation, allows these two molecules to coexist without affecting their individual pharmacodynamic profiles.
DOI: 10.1111/ijcp.12821
PubMed: 27384031
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A37
Links to Exploration step
pubmed:27384031Curation
No country items
A G Unnikrishnan<affiliation><nlm:affiliation>Chellaram Diabetes Institute, Pune, Maharashtra.</nlm:affiliation><wicri:noCountry code="subField">Maharashtra</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical use of the co-formulation of insulin degludec and insulin aspart.</title><author><name sortKey="Kumar, A" sort="Kumar, A" uniqKey="Kumar A" first="A" last="Kumar">A. Kumar</name><affiliation wicri:level="1"><nlm:affiliation>Diabetes Care & Research Centre, Patna, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Diabetes Care & Research Centre, Patna</wicri:regionArea></affiliation></author><author><name sortKey="Awata, T" sort="Awata, T" uniqKey="Awata T" first="T" last="Awata">T. Awata</name><affiliation wicri:level="1"><nlm:affiliation>Department of Diabetes, Endocrinology and Metabolism, International University of Health and Welfare Hospital, Tochigi, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Diabetes, Endocrinology and Metabolism, International University of Health and Welfare Hospital, Tochigi</wicri:regionArea></affiliation></author><author><name sortKey="Bain, S C" sort="Bain, S C" uniqKey="Bain S" first="S C" last="Bain">S C Bain</name><affiliation wicri:level="1"><nlm:affiliation>Diabetes Research Unit Cymru, Swansea University & ABM University Health Board, Swansea, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Diabetes Research Unit Cymru, Swansea University & ABM University Health Board, Swansea</wicri:regionArea></affiliation></author><author><name sortKey="Ceriello, A" sort="Ceriello, A" uniqKey="Ceriello A" first="A" last="Ceriello">A. Ceriello</name><affiliation wicri:level="1"><nlm:affiliation>Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Fulcher, G R" sort="Fulcher, G R" uniqKey="Fulcher G" first="G R" last="Fulcher">G R Fulcher</name><affiliation wicri:level="1"><nlm:affiliation>University of Sydney, Royal North Shore Hospital, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Sydney, Royal North Shore Hospital, Sydney, NSW</wicri:regionArea></affiliation></author><author><name sortKey="Unnikrishnan, A G" sort="Unnikrishnan, A G" uniqKey="Unnikrishnan A" first="A G" last="Unnikrishnan">A G Unnikrishnan</name><affiliation><nlm:affiliation>Chellaram Diabetes Institute, Pune, Maharashtra.</nlm:affiliation><wicri:noCountry code="subField">Maharashtra</wicri:noCountry></affiliation></author><author><name sortKey="Arechavaleta, R" sort="Arechavaleta, R" uniqKey="Arechavaleta R" first="R" last="Arechavaleta">R. Arechavaleta</name><affiliation wicri:level="1"><nlm:affiliation>Departamento de Endocrinologia, Universidad Autónoma de Guadalajara, Zapopan, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Departamento de Endocrinologia, Universidad Autónoma de Guadalajara, Zapopan</wicri:regionArea></affiliation></author><author><name sortKey="Gonzalez Galvez, G" sort="Gonzalez Galvez, G" uniqKey="Gonzalez Galvez G" first="G" last="Gonzalez-Gálvez">G. Gonzalez-Gálvez</name><affiliation wicri:level="1"><nlm:affiliation>Instituto Jalisciense de Investigación en Diabetes y Obesidad S.C. Guadalajara, Jalisco, México.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Mexique</country><wicri:regionArea>Instituto Jalisciense de Investigación en Diabetes y Obesidad S.C. Guadalajara, Jalisco</wicri:regionArea></affiliation></author><author><name sortKey="Hirose, T" sort="Hirose, T" uniqKey="Hirose T" first="T" last="Hirose">T. Hirose</name><affiliation wicri:level="1"><nlm:affiliation>Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University School of Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University School of Medicine, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="Home, P D" sort="Home, P D" uniqKey="Home P" first="P D" last="Home">P D Home</name><affiliation wicri:level="1"><nlm:affiliation>Newcastle University, Newcastle upon Tyne, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Newcastle University, Newcastle upon Tyne</wicri:regionArea></affiliation></author><author><name sortKey="Kaku, K" sort="Kaku, K" uniqKey="Kaku K" first="K" last="Kaku">K. Kaku</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Internal Medicine, Kawasaki Medical School, Kurashiki</wicri:regionArea></affiliation></author><author><name sortKey="Litwak, L" sort="Litwak, L" uniqKey="Litwak L" first="L" last="Litwak">L. Litwak</name><affiliation wicri:level="1"><nlm:affiliation>Endocrine, Metabolism and Nuclear Medicine Service, Diabetes Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Endocrine, Metabolism and Nuclear Medicine Service, Diabetes Section, Hospital Italiano de Buenos Aires, Buenos Aires</wicri:regionArea></affiliation></author><author><name sortKey="Madsbad, S" sort="Madsbad, S" uniqKey="Madsbad S" first="S" last="Madsbad">S. Madsbad</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Copenhagen</wicri:regionArea></affiliation></author><author><name sortKey="Pinget, M" sort="Pinget, M" uniqKey="Pinget M" first="M" last="Pinget">M. Pinget</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology, University of Strasbourg, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Endocrinology, University of Strasbourg, Strasbourg</wicri:regionArea></affiliation></author><author><name sortKey="Mehta, R" sort="Mehta, R" uniqKey="Mehta R" first="R" last="Mehta">R. Mehta</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology, National Institute of Medical Sciences and Nutrition, Salvador Zubirán, México City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Endocrinology, National Institute of Medical Sciences and Nutrition, Salvador Zubirán, México City</wicri:regionArea></affiliation></author><author><name sortKey="Mithal, A" sort="Mithal, A" uniqKey="Mithal A" first="A" last="Mithal">A. Mithal</name><affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Diabetes, Medanta the Medicity, Gurgaon, Haryana, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Division of Endocrinology and Diabetes, Medanta the Medicity, Gurgaon, Haryana</wicri:regionArea></affiliation></author><author><name sortKey="Tambascia, M" sort="Tambascia, M" uniqKey="Tambascia M" first="M" last="Tambascia">M. Tambascia</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medical Sciences, State University of Campinas, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Faculty of Medical Sciences, State University of Campinas, São Paulo</wicri:regionArea></affiliation></author><author><name sortKey="Tibaldi, J" sort="Tibaldi, J" uniqKey="Tibaldi J" first="J" last="Tibaldi">J. Tibaldi</name><affiliation wicri:level="1"><nlm:affiliation>Queens Diabetes and Endocrinology Associates, Fresh Meadows, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Queens Diabetes and Endocrinology Associates, Fresh Meadows, New York, NY</wicri:regionArea></affiliation></author><author><name sortKey="Christiansen, J S" sort="Christiansen, J S" uniqKey="Christiansen J" first="J S" last="Christiansen">J S Christiansen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Medicine - The Department of Endocrinology and Diabetes, Aarhus University Hospital, NBG, Aarhus C, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Clinical Medicine - The Department of Endocrinology and Diabetes, Aarhus University Hospital, NBG, Aarhus C</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27384031</idno><idno type="pmid">27384031</idno><idno type="doi">10.1111/ijcp.12821</idno><idno type="wicri:Area/PubMed/Corpus">001A37</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A37</idno><idno type="wicri:Area/PubMed/Curation">001A13</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A13</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical use of the co-formulation of insulin degludec and insulin aspart.</title><author><name sortKey="Kumar, A" sort="Kumar, A" uniqKey="Kumar A" first="A" last="Kumar">A. Kumar</name><affiliation wicri:level="1"><nlm:affiliation>Diabetes Care & Research Centre, Patna, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Diabetes Care & Research Centre, Patna</wicri:regionArea></affiliation></author><author><name sortKey="Awata, T" sort="Awata, T" uniqKey="Awata T" first="T" last="Awata">T. Awata</name><affiliation wicri:level="1"><nlm:affiliation>Department of Diabetes, Endocrinology and Metabolism, International University of Health and Welfare Hospital, Tochigi, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Diabetes, Endocrinology and Metabolism, International University of Health and Welfare Hospital, Tochigi</wicri:regionArea></affiliation></author><author><name sortKey="Bain, S C" sort="Bain, S C" uniqKey="Bain S" first="S C" last="Bain">S C Bain</name><affiliation wicri:level="1"><nlm:affiliation>Diabetes Research Unit Cymru, Swansea University & ABM University Health Board, Swansea, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Diabetes Research Unit Cymru, Swansea University & ABM University Health Board, Swansea</wicri:regionArea></affiliation></author><author><name sortKey="Ceriello, A" sort="Ceriello, A" uniqKey="Ceriello A" first="A" last="Ceriello">A. Ceriello</name><affiliation wicri:level="1"><nlm:affiliation>Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Fulcher, G R" sort="Fulcher, G R" uniqKey="Fulcher G" first="G R" last="Fulcher">G R Fulcher</name><affiliation wicri:level="1"><nlm:affiliation>University of Sydney, Royal North Shore Hospital, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>University of Sydney, Royal North Shore Hospital, Sydney, NSW</wicri:regionArea></affiliation></author><author><name sortKey="Unnikrishnan, A G" sort="Unnikrishnan, A G" uniqKey="Unnikrishnan A" first="A G" last="Unnikrishnan">A G Unnikrishnan</name><affiliation><nlm:affiliation>Chellaram Diabetes Institute, Pune, Maharashtra.</nlm:affiliation><wicri:noCountry code="subField">Maharashtra</wicri:noCountry></affiliation></author><author><name sortKey="Arechavaleta, R" sort="Arechavaleta, R" uniqKey="Arechavaleta R" first="R" last="Arechavaleta">R. Arechavaleta</name><affiliation wicri:level="1"><nlm:affiliation>Departamento de Endocrinologia, Universidad Autónoma de Guadalajara, Zapopan, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Departamento de Endocrinologia, Universidad Autónoma de Guadalajara, Zapopan</wicri:regionArea></affiliation></author><author><name sortKey="Gonzalez Galvez, G" sort="Gonzalez Galvez, G" uniqKey="Gonzalez Galvez G" first="G" last="Gonzalez-Gálvez">G. Gonzalez-Gálvez</name><affiliation wicri:level="1"><nlm:affiliation>Instituto Jalisciense de Investigación en Diabetes y Obesidad S.C. Guadalajara, Jalisco, México.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Mexique</country><wicri:regionArea>Instituto Jalisciense de Investigación en Diabetes y Obesidad S.C. Guadalajara, Jalisco</wicri:regionArea></affiliation></author><author><name sortKey="Hirose, T" sort="Hirose, T" uniqKey="Hirose T" first="T" last="Hirose">T. Hirose</name><affiliation wicri:level="1"><nlm:affiliation>Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University School of Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University School of Medicine, Tokyo</wicri:regionArea></affiliation></author><author><name sortKey="Home, P D" sort="Home, P D" uniqKey="Home P" first="P D" last="Home">P D Home</name><affiliation wicri:level="1"><nlm:affiliation>Newcastle University, Newcastle upon Tyne, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Newcastle University, Newcastle upon Tyne</wicri:regionArea></affiliation></author><author><name sortKey="Kaku, K" sort="Kaku, K" uniqKey="Kaku K" first="K" last="Kaku">K. Kaku</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Internal Medicine, Kawasaki Medical School, Kurashiki</wicri:regionArea></affiliation></author><author><name sortKey="Litwak, L" sort="Litwak, L" uniqKey="Litwak L" first="L" last="Litwak">L. Litwak</name><affiliation wicri:level="1"><nlm:affiliation>Endocrine, Metabolism and Nuclear Medicine Service, Diabetes Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Endocrine, Metabolism and Nuclear Medicine Service, Diabetes Section, Hospital Italiano de Buenos Aires, Buenos Aires</wicri:regionArea></affiliation></author><author><name sortKey="Madsbad, S" sort="Madsbad, S" uniqKey="Madsbad S" first="S" last="Madsbad">S. Madsbad</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Copenhagen</wicri:regionArea></affiliation></author><author><name sortKey="Pinget, M" sort="Pinget, M" uniqKey="Pinget M" first="M" last="Pinget">M. Pinget</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology, University of Strasbourg, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Endocrinology, University of Strasbourg, Strasbourg</wicri:regionArea></affiliation></author><author><name sortKey="Mehta, R" sort="Mehta, R" uniqKey="Mehta R" first="R" last="Mehta">R. Mehta</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology, National Institute of Medical Sciences and Nutrition, Salvador Zubirán, México City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Department of Endocrinology, National Institute of Medical Sciences and Nutrition, Salvador Zubirán, México City</wicri:regionArea></affiliation></author><author><name sortKey="Mithal, A" sort="Mithal, A" uniqKey="Mithal A" first="A" last="Mithal">A. Mithal</name><affiliation wicri:level="1"><nlm:affiliation>Division of Endocrinology and Diabetes, Medanta the Medicity, Gurgaon, Haryana, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Division of Endocrinology and Diabetes, Medanta the Medicity, Gurgaon, Haryana</wicri:regionArea></affiliation></author><author><name sortKey="Tambascia, M" sort="Tambascia, M" uniqKey="Tambascia M" first="M" last="Tambascia">M. Tambascia</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medical Sciences, State University of Campinas, São Paulo, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Faculty of Medical Sciences, State University of Campinas, São Paulo</wicri:regionArea></affiliation></author><author><name sortKey="Tibaldi, J" sort="Tibaldi, J" uniqKey="Tibaldi J" first="J" last="Tibaldi">J. Tibaldi</name><affiliation wicri:level="1"><nlm:affiliation>Queens Diabetes and Endocrinology Associates, Fresh Meadows, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Queens Diabetes and Endocrinology Associates, Fresh Meadows, New York, NY</wicri:regionArea></affiliation></author><author><name sortKey="Christiansen, J S" sort="Christiansen, J S" uniqKey="Christiansen J" first="J S" last="Christiansen">J S Christiansen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Medicine - The Department of Endocrinology and Diabetes, Aarhus University Hospital, NBG, Aarhus C, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Clinical Medicine - The Department of Endocrinology and Diabetes, Aarhus University Hospital, NBG, Aarhus C</wicri:regionArea></affiliation></author></analytic><series><title level="j">International journal of clinical practice</title><idno type="eISSN">1742-1241</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Glucose</term><term>Clinical Trials, Phase II as Topic</term><term>Clinical Trials, Phase III as Topic</term><term>Diabetes Mellitus, Type 1 (drug therapy)</term><term>Diabetes Mellitus, Type 2 (drug therapy)</term><term>Drug Administration Schedule</term><term>Drug Substitution</term><term>Humans</term><term>Hypoglycemic Agents (adverse effects)</term><term>Hypoglycemic Agents (pharmacology)</term><term>Hypoglycemic Agents (therapeutic use)</term><term>Insulin Aspart (administration & dosage)</term><term>Insulin Aspart (adverse effects)</term><term>Insulin Aspart (pharmacology)</term><term>Insulin, Long-Acting (administration & dosage)</term><term>Insulin, Long-Acting (adverse effects)</term><term>Insulin, Long-Acting (pharmacology)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Calendrier d'administration des médicaments</term><term>Diabète de type 1 (traitement médicamenteux)</term><term>Diabète de type 2 (traitement médicamenteux)</term><term>Essais cliniques de phase II comme sujet</term><term>Essais cliniques de phase III comme sujet</term><term>Glycémie</term><term>Humains</term><term>Hypoglycémiants (effets indésirables)</term><term>Hypoglycémiants (pharmacologie)</term><term>Hypoglycémiants (usage thérapeutique)</term><term>Insuline Asparte (administration et posologie)</term><term>Insuline Asparte (effets indésirables)</term><term>Insuline Asparte (pharmacologie)</term><term>Insuline à longue durée d'action (administration et posologie)</term><term>Insuline à longue durée d'action (effets indésirables)</term><term>Insuline à longue durée d'action (pharmacologie)</term><term>Résultat thérapeutique</term><term>Substitution de médicament</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Insulin Aspart</term><term>Insulin, Long-Acting</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hypoglycemic Agents</term><term>Insulin Aspart</term><term>Insulin, Long-Acting</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Hypoglycemic Agents</term><term>Insulin Aspart</term><term>Insulin, Long-Acting</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hypoglycemic Agents</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Blood Glucose</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Insuline Asparte</term><term>Insuline à longue durée d'action</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 1</term><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hypoglycémiants</term><term>Insuline Asparte</term><term>Insuline à longue durée d'action</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Hypoglycémiants</term><term>Insuline Asparte</term><term>Insuline à longue durée d'action</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 1</term><term>Diabète de type 2</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hypoglycémiants</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials, Phase II as Topic</term><term>Clinical Trials, Phase III as Topic</term><term>Drug Administration Schedule</term><term>Drug Substitution</term><term>Humans</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Calendrier d'administration des médicaments</term><term>Essais cliniques de phase II comme sujet</term><term>Essais cliniques de phase III comme sujet</term><term>Glycémie</term><term>Humains</term><term>Résultat thérapeutique</term><term>Substitution de médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To provide a review of the available data and practical use of insulin degludec with insulin aspart (IDegAsp). Premixed insulins provide basal and prandial glucose control; however, they have an intermediate-acting prandial insulin component and do not provide as effective basal coverage as true long-acting insulins, owing to the physicochemical incompatibility of their individual components, coupled with the inflexibility of adjustment. The molecular structure of the co-formulation of IDegAsp, a novel insulin preparation, allows these two molecules to coexist without affecting their individual pharmacodynamic profiles.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27384031</PMID><DateCreated><Year>2016</Year><Month>07</Month><Day>28</Day></DateCreated><DateCompleted><Year>2017</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1742-1241</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>8</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of clinical practice</Title><ISOAbbreviation>Int. J. Clin. Pract.</ISOAbbreviation></Journal><ArticleTitle>Clinical use of the co-formulation of insulin degludec and insulin aspart.</ArticleTitle><Pagination><MedlinePgn>657-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ijcp.12821</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To provide a review of the available data and practical use of insulin degludec with insulin aspart (IDegAsp). Premixed insulins provide basal and prandial glucose control; however, they have an intermediate-acting prandial insulin component and do not provide as effective basal coverage as true long-acting insulins, owing to the physicochemical incompatibility of their individual components, coupled with the inflexibility of adjustment. The molecular structure of the co-formulation of IDegAsp, a novel insulin preparation, allows these two molecules to coexist without affecting their individual pharmacodynamic profiles.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Clinical evidence in phase 2/3 trials of IDegAsp efficacy and safety in type 1 and type 2 diabetes mellitus (T1DM and T2DM) have been assessed and summarised.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In people with T2DM, once- and twice-daily dosing provides similar overall glycaemic control (HbA1c ) to current modern insulins, but with lower risk of nocturnal hypoglycaemia. In prior insulin users, glycaemic control was achieved with lower or equal insulin doses vs. other basal+meal-time or premix insulin regimens. In insulin-naïve patients with T2DM, IDegAsp can be started once or twice-daily, based on individual need. People switching from more than once-daily basal or premix insulin therapy can be converted unit-to-unit to once-daily IDegAsp, although this strategy should be assessed by the physician on an individual basis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IDegAsp offers physicians and people with T2DM a simpler insulin regimen than other available basal-bolus or premix-based insulin regimens, with stable daytime basal coverage, a lower rate of hypoglycaemia and some flexibility in injection timing compared with premix insulins.</AbstractText><CopyrightInformation>© 2016 John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Diabetes Care & Research Centre, Patna, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awata</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Diabetes, Endocrinology and Metabolism, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bain</LastName><ForeName>S C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Diabetes Research Unit Cymru, Swansea University & ABM University Health Board, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceriello</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS MultiMedica, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulcher</LastName><ForeName>G R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>University of Sydney, Royal North Shore Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unnikrishnan</LastName><ForeName>A G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Chellaram Diabetes Institute, Pune, Maharashtra.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arechavaleta</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Endocrinologia, Universidad Autónoma de Guadalajara, Zapopan, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez-Gálvez</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Instituto Jalisciense de Investigación en Diabetes y Obesidad S.C. Guadalajara, Jalisco, México.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirose</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Home</LastName><ForeName>P D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaku</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litwak</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Endocrine, Metabolism and Nuclear Medicine Service, Diabetes Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsbad</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinget</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, University of Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, National Institute of Medical Sciences and Nutrition, Salvador Zubirán, México City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mithal</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Diabetes, Medanta the Medicity, Gurgaon, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tambascia</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medical Sciences, State University of Campinas, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tibaldi</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Queens Diabetes and Endocrinology Associates, Fresh Meadows, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christiansen</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine - The Department of Endocrinology and Diabetes, Aarhus University Hospital, NBG, Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Clin Pract</MedlineTA><NlmUniqueID>9712381</NlmUniqueID><ISSNLinking>1368-5031</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D049528">Insulin, Long-Acting</NameOfSubstance></Chemical><Chemical><RegistryNumber>54Q18076QB</RegistryNumber><NameOfSubstance UI="C571886">insulin degludec</NameOfSubstance></Chemical><Chemical><RegistryNumber>D933668QVX</RegistryNumber><NameOfSubstance UI="D061267">Insulin Aspart</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061267" MajorTopicYN="N">Insulin Aspart</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049528" MajorTopicYN="N">Insulin, Long-Acting</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27384031</ArticleId><ArticleId IdType="doi">10.1111/ijcp.12821</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001A13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:27384031
|texte= Clinical use of the co-formulation of insulin degludec and insulin aspart.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27384031" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |